Drug Trial Radar · NCT07277933
Efficacy and Safety of KHN702 Tablets in Moderate to Severe Post-operative Pain Subjects
Last checked: Nov 20, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Dec 2025
Primary completion
Feb 2026
Study completion Feb 2026
Sponsor
- Lead sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, parallel-group clinical trial. To preliminarily evaluate the safety and efficacy of KHN702 tablets in moderate to severe post-operative pain patients.
Conditions
- Postoperative Pain
Interventions
KHN702Drug
KHN702 tablet for oral administration
KHN702 placeboDrug
KHN702 placebo tablet for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-weighted the Sum of Pain Intensity Differences in Pain Score 0 to 48 hours after the first doseTime frame: 48 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.